TL/DR –
The State of Possible Conference discussed the state of drug pricing and the effects of potential solutions. The discussions raised the importance of effectively communicating the value of new therapies and the need for incentives and collaboration to support drug development. Concerns were raised about the impact of legislative changes, particularly the Inflation Reduction Act, on drug pricing and the predictability essential for biopharma companies.
“`html
Reflecting on the State of Possible Conference: Innovation and Affordability
The annual State of Possible Conference provided an insider’s look into the passion and purpose that drive scientific innovations much before they become popular news topics. One word seemed to prominently feature in recent health-related news: Affordability.
With the cost of health care and prescription drugs becoming a primary concern for many Americans, legislators at both federal and state levels are considering policies that could change the landscape for drug developers and consumers at pharmacies. The State of Possible Conference held open discussions about drug pricing and potential implications of proposed solutions.
An Honest Dialogue
John Stanford, partner and CEO at Novel Strategies, moderated a panel focusing on the price of innovation, describing it as “an honest conversation.” This discussion touched on several truths about the industry impacting the cost of medicines, from R&D expenses, use of AI, to geopolitical factors. A major part of the conversation revolved around the role of communication in shaping perceptions about drug pricing in the US.
Chris Garabedian, venture portfolio manager at Perceptive Advisors and Chairman & CEO of Xontogeny, highlighted the overall cost of health care. He pointed out that only 10-15% of healthcare spending goes to branded pharmaceuticals, and the efficiency of providing treatments via prescription or injections is an efficient healthcare deployment method.
Garabedian underlined the industry’s struggle to effectively communicate how these novel therapies have greatly reduced the cost and burden of treating diseases in the US. He gave examples where traditional treatment methods are outdated and expensive compared to receiving therapy in a cost-effective setup. Garabedian emphasized the need to better explain that even if branded drugs have a high initial cost, they are the most efficient way to treat diseases.
Melanie Whittington, managing director of the Leerink Center for Pharmacoeconomics, urged the industry to be more transparent about price discussions. According to her, the biopharma industry’s mixed reputation among Americans is due to the lack of open conversation about the value of medicine. She stressed the need to discuss, think about, and appreciate the significant societal, health system, and patient impacts of the products developed by the biopharma industry.
Role of Federal Policymakers and Incentives
The role of federal policymakers in creating an environment conducive for investment and innovation also came up in discussions on drug pricing. Regulators and Congress have various tools at their disposal to incentivize drug development. However, they also have the potential to enact policies that could inadvertently impact innovation.
According to Garabedian, federal incentives such as the FDA’s priority review vouchers for therapies treating rare pediatric diseases have shown positive outcomes. Nevertheless, he suggested that the biotech industry could benefit from more such programs and incentives.
Scott Robertson, co-founder and managing partner at Dauntless Ventures, emphasized the need for the biotech industry to have a unified approach in engaging with the U.S government on important issues.
Disruptions and Uncertainty in Washington
Predictability plays a crucial role in helping biotech companies plan for a sustainable future. However, legislative changes like the Inflation Reduction Act (IRA) have introduced uncertainties into the equation of drug pricing. Chris Viehbacher, president and CEO of Biogen, commented on this uncertainty, noting that the IRA has effectively shortened the patent life of a drug.
The FDA has traditionally been a beacon of stability for biotech companies. However, recent staff cutbacks and leadership changes have thrown up new questions about the agency’s future. Tamar Thompson, VP, patient experience and insights at Alexion, AstraZeneca Rare Disease, highlighted the tremendous uncertainty at the agency.
Massachusetts Leads the Way
Massachusetts Governor Maura Healey acknowledged the challenges federal changes have brought for the industry and emphasized the state’s strong response. In 2025, she signed legislation to reduce insurer cost sharing on prescription medicines. The state has since worked with insurers to streamline prior authorization practices that often delay care and worsen outcomes.
Through its commitment to public-private partnership, the state has created a Health Care Affordability Working Group tasked with advancing proposals to reduce health care costs across the system.
Remaining Hopeful
Though the debate around drug pricing can seem overwhelming, the State of Possible Conference was a reminder that progress requires time, open discussions, and commitment. As Governor Healey put it, “You’re in the business of hope.”
Andrew Wishon is an associate director at Real Chemistry, a tier-one partner to the world’s most innovative life sciences and health care companies. He is the editor-in-chief of Real Chemistry’s Value Report, a free weekly newsletter on biopharma policy and pricing.
“`
—
Read More US Economic News